SII and DNDi will develop a work plan to implement research and development, Phase 3 clinical trials, and access activities, ...

Serum Institute of India and DNDi partner to develop affordable dengue treatment, conducting Phase III trials in multiple countries.

SII partners with DNDi to develop affordable dengue treatment, aiming to save lives in LMICs and endemic countries.

Serum Institute of India and DNDi collaborate to accelerate development of an affordable dengue monoclonal antibody treatment ...

Serum Institute and DNDi sign MoU to develop and scale a dengue monoclonal antibody vaccine with Phase 3 trials in India, ...

The Serum Institute of India (SII), the world’s largest vaccine manufacturer and Drugs for Neglected Diseases initiative ...

Hyderabad based vaccine maker Bharat Biotech International Limited (BBIL) has in-licensed a potential vaccine candidate for ...

An indigenously developed gene therapy for specific blood cancers has shown a 73 per cent response rate among patients in India, according to results of clinical trials published in The Lancet ...

INDIA stands at a crossroads in the global clinical trials market. Despite its vast and diverse patient pool, cost-effective medical ecosystem, and expanding hospital network, the country holds a ...

India initiates clinical trials for the first human-source MTBVAC vaccine, assessing safety and efficacy for all age groups. Developed by Biofabri, the vaccine collaboration with Bharat Biotech ...

The clinical trials of MTBVAC, the Spanish tuberculosis vaccine candidate, the first live attenuated vaccine of Mycobacterium tuberculosis isolated from a human, commenced in India. The trials are ...

Mistrust, arbitrary decree and lax regulations have historically plagued clinical trials in India. More than evidence-based assessment, it was a technicality in India’s ‘New Drugs and Clinical ...